GeNeuro S.A. (GNRRF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeNeuro S.A. (GNRRF) trades at $4.55. GeNeuro SA is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for GNRRF: GNRRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNRRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on GNRRF.
How is this calculated? →GeNeuro S.A. (GNRRF) Healthcare & Pipeline Overview
GeNeuro SA is a Swiss clinical-stage biopharmaceutical firm specializing in neurodegenerative and autoimmune disease treatments. Their primary asset, temelimab, a monoclonal antibody targeting HERV-W ENV, is undergoing clinical trials for multiple sclerosis, type 1 diabetes, and chronic inflammatory demyelinating polyneuropathy, positioning them in a competitive biotech landscape.
What Is the Investment Thesis for GNRRF?
GeNeuro's investment thesis hinges on the successful development and commercialization of temelimab, its lead monoclonal antibody targeting HERV-W ENV. The potential market for multiple sclerosis, type 1 diabetes, and other neurodegenerative diseases is substantial. Positive Phase IIb clinical trial results for multiple sclerosis provide a foundation for further development. Key value drivers include the progression of temelimab through clinical trials, securing partnerships for late-stage development and commercialization, and expanding the pipeline to address other HERV-W ENV-related diseases. A beta of 0.41 suggests lower volatility than the overall market. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established pharmaceutical companies. Successful navigation of these challenges could unlock significant value for investors.
Based on FMP financials and quantitative analysis
GNRRF Key Highlights
Temelimab, GeNeuro's lead candidate, has completed Phase IIb clinical trial for multiple sclerosis, showing potential efficacy.
- GeNeuro has ongoing Phase IIa trials for temelimab in type 1 diabetes, expanding its therapeutic applications.
- The company has a cooperative research agreement with The National Institute of Neurological Disorders and Stroke for amyotrophic lateral sclerosis.
- GeNeuro collaborates with Northwestern University to study HERV-W ENV in long-haul COVID patients.
- GeNeuro's low beta of 0.41 indicates lower volatility compared to the broader market.
Who Are GNRRF's Competitors?
GNRRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSTG Biostage, Inc. | $4.03 | +0.75% | $57.8M | 44 |
| HITC Healthcare Integrated Technologies, Inc. | $0.29 | +0.00% | $52.8M | 38 |
| HRPMF Herantis Pharma Oyj | $3.51 | +0.00% | $59.5M | 44 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| KDEVF Karolinska Development AB (publ) | $0.26 | +0.00% | $68.9M | 56 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNRRF's Key Strengths?
Novel therapeutic approach targeting HERV-W ENV.
- Promising Phase IIb clinical trial results for multiple sclerosis.
- Collaborative research agreements with leading institutions.
- Experienced management team.
What Are GNRRF's Weaknesses?
Clinical-stage company with no approved products.
- Reliance on the success of temelimab.
- Limited financial resources.
- OTC market listing.
What Could Drive GNRRF Stock Higher?
Announcement of Phase IIa clinical trial results for temelimab in type 1 diabetes.
- Potential partnership agreements for late-stage development and commercialization of temelimab.
- Advancement of temelimab through clinical trials for multiple sclerosis.
- Expansion of the pipeline to address other HERV-W ENV-related diseases.
- Research collaboration with Northwestern University to study HERV-W ENV in long-haul COVID patients.
What Are the Key Risks for GNRRF?
Failure to secure regulatory approval for temelimab.
- Clinical trial failures or unexpected safety concerns.
- Competition from established pharmaceutical companies with greater resources.
- Limited financial resources and reliance on external funding.
- Risks associated with OTC market listing, including limited liquidity and disclosure.
What Are the Growth Opportunities for GNRRF?
- Expansion into Long-Haul COVID Market: GeNeuro's research collaboration with Northwestern University to study HERV-W ENV in long-haul COVID patients presents a significant growth opportunity. With a substantial number of individuals experiencing long-term effects post-COVID-19 infection, the market for effective treatments is expanding. If GeNeuro can demonstrate that temelimab or another HERV-W ENV-targeting therapy can alleviate these symptoms, it could capture a significant share of this emerging market. Timeline: Clinical trials and potential market entry within the next 3-5 years.
- Advancement of Temelimab in Type 1 Diabetes: The ongoing Phase IIa clinical trial of temelimab in type 1 diabetes represents a key growth opportunity. Type 1 diabetes is a chronic autoimmune disease with a significant unmet medical need. Positive clinical trial results could lead to regulatory approval and commercialization, generating substantial revenue. Timeline: Phase III trials and potential market launch within 5-7 years.
- Development of Therapies for Amyotrophic Lateral Sclerosis (ALS): GeNeuro's cooperative research agreement with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for ALS offers a long-term growth opportunity. ALS is a devastating neurodegenerative disease with limited treatment options. Successful development of an effective therapy could generate significant revenue and improve patient outcomes. Timeline: Preclinical and clinical development over the next 5-10 years.
- Partnerships for Late-Stage Development and Commercialization: GeNeuro can pursue strategic partnerships with larger pharmaceutical companies to fund late-stage clinical trials and commercialize temelimab or other pipeline assets. These partnerships can provide financial resources, expertise, and access to established distribution networks. This strategy can accelerate the development and commercialization process and maximize the value of GeNeuro's assets. Timeline: Ongoing, with potential partnerships in the next 1-3 years.
- Expansion of Pipeline to Address Other HERV-W ENV-Related Diseases: GeNeuro can expand its pipeline by identifying and developing therapies for other diseases in which HERV-W ENV plays a significant role. This could include other neurodegenerative diseases, autoimmune disorders, and even certain types of cancer. Expanding the pipeline diversifies the company's risk and increases its long-term growth potential. Timeline: Ongoing research and development efforts, with potential new pipeline candidates in the next 3-5 years.
What Are GNRRF's Competitive Advantages?
- Proprietary technology targeting HERV-W ENV.
- Patent protection for temelimab and other pipeline assets.
- Clinical trial data demonstrating efficacy in multiple sclerosis.
- Collaborative research agreements with leading institutions.
- Expertise in the field of human endogenous retroviruses.
What Does GNRRF Do?
GeNeuro SA, established in 2006 and headquartered in Plan-les-Ouates, Switzerland, is a biopharmaceutical company dedicated to developing therapies for neurodegenerative and autoimmune diseases. The company's core focus lies in neutralizing the pathogenic effect of human endogenous retrovirus W envelope protein (HERV-W ENV), which is implicated in several diseases. Their lead therapeutic candidate, temelimab, a monoclonal antibody, is designed to block HERV-W ENV's activity. Temelimab has completed a Phase IIb clinical trial for multiple sclerosis, demonstrating promising results. Currently, it is in Phase IIa clinical trials for type 1 diabetes and Phase I for chronic inflammatory demyelinating polyneuropathy. GeNeuro also has collaborative research and development agreements with institutions like The National Institute of Neurological Disorders and Stroke to explore novel therapeutic antibodies for amyotrophic lateral sclerosis. Additionally, they collaborate with academic centers to investigate inflammatory psychosis and with Northwestern University and the International Center for Infectiology Research to study HERV-W ENV in long-haul COVID patients. GeNeuro's strategy centers on addressing unmet medical needs in areas where HERV-W ENV plays a significant role in disease pathology.
What Products and Services Does GNRRF Offer?
- Develop drugs for neurodegenerative diseases.
- Develop drugs for autoimmune diseases.
- Focus on neutralizing the pathogenic effect of HERV-W ENV protein.
- Develop monoclonal antibody therapies.
- Conduct clinical trials for multiple sclerosis.
- Conduct clinical trials for type 1 diabetes.
- Collaborate with research institutions to develop new therapies.
How Does GNRRF Make Money?
- Develop and patent novel therapeutic antibodies.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA and EMA.
- Potentially partner with larger pharmaceutical companies for commercialization.
- Generate revenue through product sales and licensing agreements.
What Industry Does GNRRF Operate In?
GeNeuro operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for neurodegenerative and autoimmune disease treatments is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Companies like Biogen and Roche are major players in the multiple sclerosis market, while others focus on type 1 diabetes and related autoimmune disorders. GeNeuro's focus on HERV-W ENV as a therapeutic target differentiates it from competitors, but it also introduces unique scientific and regulatory challenges.
Who Are GNRRF's Key Customers?
- Patients with multiple sclerosis.
- Patients with type 1 diabetes.
- Patients with amyotrophic lateral sclerosis (potential).
- Patients with long-haul COVID (potential).
- Healthcare providers who prescribe GeNeuro's therapies.
Company Profile
GeNeuro S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Plan-les-Ouates, CH. The company is led by CEO Jesus Martin-Garcia. GNRRF has traded publicly since 2017.
Key Financial Metrics
Return on equity for GeNeuro S.A. stands at 239.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.37 means current liabilities exceed short-term assets, a liquidity point worth watching.
GNRRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel therapeutic approach targeting HERV-W ENV.
- Promising Phase IIb clinical trial results for multiple sclerosis.
- Collaborative research agreements with leading institutions.
- Experienced management team.
Bear Case
- Clinical-stage company with no approved products.
- Reliance on the success of temelimab.
- Limited financial resources.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
GNRRF Latest News
No recent news available for GNRRF.
GNRRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNRRF.
Price Targets
Wall Street price target analysis for GNRRF.
GNRRF MoonshotScore
What does this score mean?
The MoonshotScore rates GNRRF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jesus Martin-Garcia
CEO
Jesus Martin-Garcia serves as the CEO of GeNeuro SA, bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies, focusing on strategic development, fundraising, and commercialization of innovative therapies. He has a proven track record in building and managing successful biotech ventures. His expertise spans across multiple therapeutic areas, including neurology and immunology.
Track Record: Under Jesus Martin-Garcia's leadership, GeNeuro has advanced temelimab through Phase IIb clinical trials for multiple sclerosis and initiated Phase IIa trials for type 1 diabetes. He has also secured collaborative research agreements with leading institutions, expanding the company's pipeline and scientific expertise. His strategic decisions have focused on maximizing the value of GeNeuro's HERV-W ENV-targeting platform.
GNRRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GeNeuro (GNRRF) may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited or no financial disclosures, making it difficult for investors to assess their financial health and operational performance. This tier is generally associated with higher risk and greater potential for fraud or manipulation compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low trading volume and liquidity can lead to price volatility and difficulty in executing trades.
- OTC listing may indicate a higher risk of delisting or regulatory scrutiny.
- The company may not meet the listing requirements of major exchanges, limiting access to capital.
- Potential for pump-and-dump schemes and other forms of market manipulation.
- Verify the company's registration and regulatory filings with the SEC or other relevant authorities.
- Review the company's financial statements, if available, and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity and trading volume of the stock.
- Be aware of the potential risks associated with OTC investments.
- Consult with a financial advisor before investing.
- Clinical-stage biopharmaceutical company with ongoing clinical trials.
- Collaborative research agreements with reputable institutions.
- Focus on addressing unmet medical needs in neurodegenerative and autoimmune diseases.
- Presence of a CEO with experience in the biotechnology industry.
- Patent protection for its lead therapeutic candidate, temelimab.
What Investors Ask About GeNeuro S.A. (GNRRF) — Healthcare
What does GeNeuro S.A. do?
GeNeuro S.A. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and autoimmune diseases. Their primary focus is on neutralizing the pathogenic effects of the human endogenous retrovirus W envelope protein (HERV-W ENV).
What are the main risks for GNRRF?
The main risks for GeNeuro S.A. include the inherent uncertainties of clinical development, such as the possibility of clinical trial failures or unexpected safety concerns. Regulatory hurdles and competition from established pharmaceutical companies with greater resources also pose significant risks. As an OTC-listed company, GNRRF faces additional risks related to limited liquidity, disclosure requirements, and potential market manipulation.
What are the key factors to evaluate for GNRRF?
Evaluate GNRRF on fundamentals, analyst consensus, and risk factors. GeNeuro's investment thesis hinges on the successful development and commercialization of temelimab, its lead monoclonal antibody targeting HERV-W ENV. Not financial advice.
How frequently does GNRRF data refresh on this page?
GNRRF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNRRF's recent stock price performance?
GeNeuro S.A. (GNRRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach targeting HERV-W ENV. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNRRF overvalued or undervalued right now?
GeNeuro S.A. (GNRRF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GNRRF before investing?
Before investing in GeNeuro S.A. (GNRRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNRRF to a portfolio?
Key strength of GeNeuro S.A. (GNRRF): Novel therapeutic approach targeting HERV-W ENV. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.
- OTC market investments carry higher risks than exchange-listed stocks.